Idarubicin
Idarubicin is an anthracycline antileukemic medication renowned for its significant role in managing various forms of leukemia. As a derivative of daunorubicin, this molecule exhibits increased lipophilicity, which expedites its cellular uptake. Notably, its mechanism hinges on DNA interaction and consequential obstruction of the enzyme topoisomerase II.
Chemical Characteristics[edit | edit source]
Idarubicin, or 4-demethoxydaunorubicin, is distinguishable from daunorubicin due to its absent methoxy group. This structural deviation accentuates its lipophilic traits, boosting cellular absorption[1].
Mechanism of Action[edit | edit source]
Its antileukemic activities are ascribed to several interconnected mechanisms:
- DNA Interaction: Idarubicin integrates with DNA, obstructing the DNA's inherent flexibility.
- Topoisomerase II Inhibition: It impedes the enzyme topoisomerase II, blocking the unwinding of DNA strands[2].
- Histone Eviction: Like other anthracyclines, idarubicin induces histone removal from chromatin, potentially modulating gene expression.
Therapeutic Use[edit | edit source]
Categorized within antitumor antibiotics, its clinical implications comprise:
- Synergy with cytosine arabinoside for first-line treatment against acute myeloid leukemia (AML)[3].
- Addressing acute lymphoblastic leukemia (ALL).
- Intervention in Chronic myelogenous leukemia (CML) during its blast crisis phase.
Trade names differ based on regional availabilities:
- Zavedos in the UK
- Idamycin in the USA[4].
Adverse Effects[edit | edit source]
Treatment recipients might encounter several side effects, common ones being:
- Diarrhea
- Stomach cramps
- Nausea
- Vomiting
Healthcare practitioners should closely monitor these signs to ensure patients' comfort and therapy compliance.
Conclusion[edit | edit source]
Idarubicin remains a linchpin in leukemia treatment. Its distinct mode of action and established efficacy afford patients grappling with these blood malignancies a beacon of hope. Yet, the pivotal task remains to juxtapose its therapeutic advantages with potential adverse events, ensuring paramount patient care.
References[edit | edit source]
- ↑ Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 Jun;56(2):185-229.
- ↑ Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994 May;45(5):649-56.
- ↑ Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 Jan 15;79(2):313-9.
- ↑ Thomas X, Archimbaud E. Idarubicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 1997 Oct;23(5-6):257-66.
| Idarubicin Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
